Chinese phase 2 comparing BGM0504 with semaglutide in obesity completes
The investigator-initiated, randomized, open-label study measured insulin sensitivity and body weight, with the Second Affiliated Hospital of Soochow University as sponsor.
PR
By Priya Raman · Science Reporter
Sep 23 08:00 ETSource: ClinicalTrials.gov
The wire
- 01ClinicalTrials.gov record NCT07836140 lists a completed phase 2 active-controlled trial of BGM0504 injection versus semaglutide in obese and overweight subjects, started 22 April 2024.
- 02BGM0504 is one of several Chinese dual incretin candidates being benchmarked directly against semaglutide, a comparison operators and clinicians will track as supply diversifies.
- 03No results are posted in the registry entry; the trial is open-label and investigator-initiated, so effect sizes and safety data await publication.
From the source
Read at clinicaltrials.govA Study Comparing the Effects of BGM0504 Injection and Semaglutide Injection on Obese Subjects.
NCT07836140 · PHASE2 · COMPLETED · Sponsor: Second Affiliated Hospital of Soochow University · Conditions: Obesity / Overweight.
Source URL https://clinicaltrials.gov/study/NCT07836140
